A substantial number of patients with gout has been shown to produce excessive amounts of uric acid (1) (2) (3) (4) . This overproduction has been demonstrated by the excretion of greater than normal amounts of uric acid in the urine, or an excessive incorporation of isotopically labeled glycine into urinary uric acid. The present day treatment of tophaceous gout consists primarily in the administration of uricosuric agents to increase the renal excretion of the uric acid formed, with use of colchicine, ACTH gel, or phenylbutazone for management of the acute attacks. Control of the production of uric acid has been of necessity confined to limiting the purine and protein content of the diet (5) .
A logical approach to the treatment of those patients who overproduce uric acid would be to inhibit the excessive production by pharmacologic agents. In recent years several compounds have been reported to interfere with purine biosynthesis. Two such compounds, azaserine (o-diazoacetyl-L-serine) and 6-diazo-5-oxo-L-norleucine (DON), have been shown to suppress the formation of purines in bacteria (6) , and Krakoff and Karnofsky have shown that DON inhibits uric acid production in the pigeon (7) . Both compounds are structural analogs of glutamine (see Figure 1 ) and both have been used in the human as potential chemotherapeutic agents against cancer (8. 9). Using partially purified enzyme systems, Levenberg, Melnick and Buchanan (10) demonstrated that these agents do indeed prevent the synthesis of inosinic acid by blocking the utilization of glutamine in the enzymatic conversion of formylglycinamide ribotide to formylglycinamidine ribotide (Figure 2 ). DON was found to be the more potent inhibitor of the enzyme system, requiring only 0.025 the concentra-* A preliminary report of this work has been published in abstract form (J. clin. Invest. 1959, 38, 1008).
tion of azaserine to obtain the same degree of inhibition. Although glutamine is also required in the first step in purine biosynthesis, these agents are less effective inhibitors of this earlier reaction. Zuckerman, Drell and Levin (11) have shown that azaserine reduced the incorporation of glycine-1-C14 into urinary uric acid in gouty humans, but did not alter either the serum urate levels or the urinary excretion of uric acid. The purpose of our study was to observe the effect of the administration of DON on uric acid production in gouty patients, as measured by changes in the serum urate levels and urinary excretion of uric acid, and by the incorporation of glycine-l-C'4 into urinary uric acid.
METHODS
Six male patients with gout and one with urate renal lithiasis and essential hyperuricemia were studied during hospitalization. They were all maintained on a standard 2,600 calorie, 70 g protein diet, essentially free of purines. At least five days were allowed for equilibration before studies were begun. Daily 24 hour urine collections were preserved with toluene at room temperature. The uric acid determinations of both urine and serum were made by means of an enzymatic spectrophotometric assay (12) . Urinary creatinine was determined by the method of Taussky (13) . DON provided by the Cancer Chemotherapy National Service Center was freshly made up in solution at the beginning of each study and stored in the frozen state. It was given by the intramuscular route, either 10 mg daily or in divided doses of 2.5 or 5 mg every six hours. Isotopically labeled compounds were administered on the third day of DON therapy immediately following DON injection. Glycine-l-C' (obtained (14) . 1 The glycine pool, contributing to hippuric acid, was sampled by administering 450 mg of sodium benzoate intravenously, collecting urine for a two hour period immediately following the injection, and isolating hippuric acid from the specimen. Such sampling was done six hours after the initial administration of glycine-l-C1' and during the first two hours of the collection period on the succeeding second, third, fifth and seventh days.
A period of at least three months was allowed between control and DON studies to allow for elimination of most of the C1' and correction was made for residual C14. Hippuric acid was isolated by extraction with ether and recrystallization from hot water (15) . Urinary creatinine, as the double zinc salt (16), was isolated from urine. Uric acid was isolated from aliquots of urine by adsorption on activated charcoal (17) , or by preliminary precipitation as a copper salt when urine volumes exceeded 1,500 ml per day (18) . Radioactivity was determined using an end-window gas flow counter (Nuclear, Chicago) from planchets plated at infinite thickness with sufficient time for counting to produce an error of not more than 3 per cent. The N15 content of uric acid was determined in a Consolidated-Nier mass spectrometer following preliminary digestion (19) .
RESULTS
The effect of the administration of DON on the serum urate levels, and on the 24-hour urinary uric acid excretion values in the two patients who demonstrated the greatest response to DON, are shown in Figure 3 . The results obtained in all patients are presented in Table I . Even though the data in this table are presented in a manner that would emphasize small differences, i.e., by comparing the average of several days during the pretreatment period with the lowest values obtained during treatment, the differences are not great. In four patients the difference in urinary uric acid excretion was of the order of 20 per cent. Two patients showed a slight increase in serum urate levels during DON therapy. These two patients both had tophaceous gout and the increased miscible urate pool may have prevented the decline of their serum urate levels and urinary uric acid excretion which might otherwise have resulted from a decrease in urate production.
A more sensitive index of purine biosynthesis is provided by the incorporation of glycine-l-C14 1 We are indebted to Miss Jean Benedict for providing the uric acid-1,3-N"5. into urinary uric acid. Figure 4 shows the effect of DON therapy on the specific activity of C14 in urinary uric acid; Figure 5 shows the cumulative incorporation of C14 into urinary uric acid in three patients. From Table II it is apparent that Patients W. M. and F. J., who failed to show a decline in serum urate during therapy, nevertheless showed a substantially decreased incorporation of glycine-1-C14 into uric acid indicative of a depressed purine biosynthesis accompanying DON therapy. In two of these patients corrections were made for the dynamics of the urate pool, as evidenced 10 5
Erosions of oral mucosa on day 5 of therapy R. J. 10 5 Erosions of oral mucosa on day 3 of higher dose 20 3 Asymptomatic duodenal ulcer demonstrated by X-ray (Films taken at another hospital 2 months previously showed a deformed duodenum) F. J. 5 5
None N. M. 5 9 Erosions of oral mucosa on day 5 of higher dose 10 6 Asymptomatic duodenal ulcer demonstrated on X-ray J. S. 10 6
Erosions of oral mucosa on day 6 Negative upper GI X-ray 24 per cent of the control value. In Patient F. J., 5 mg of DON per day resulted in a reduction to 68 per cent of the control value. The specific activity of the glycine pools sampled by hippuric acid and by creatinine was not significantly altered following DON administration.
The toxic effects consisting of a sore mouth, occasionally with evidence of shallow erosions of the mucous membrane of the under lip, were observed at the end of five days in five patients (Table III) Thus, maximal effects of DON were obtained at a time when glycine-1-C14 in the body had its highest specific activity. A compensatory overproduction of uric acid during the remainder of the day may have masked such a suppression at a gross level.
Upon discontinuing DON therapy, the serum urate showed a rebound, similar to that shown in Figure 3 (Patient R. J.), to values higher than those of the control period in five of the seven patients studied. Such transient elevations may well be related to the operation of a homeostatic control of purine synthesis (21, 22) similar to that described for pyrimidine synthesis in bacteria (23) . A derangement of such homeostatic control can be produced by the drug 2-ethylamino-1,3,4-thiadiazole (24, 25) . A constitutional derangement in such a controlling mechanism has been proposed to account for the increased uric acid synthesis seen in some cases of gout. A suppression of purine biosynthesis has also been produced by administering 4-amino-5-imidazolecarboxamide (21) . This substance, however, is itself converted to uric acid and so is of no value in treatment of the excessive production of uric acid seen in gout.
A considerable variability in responsiveness of different patients to a given dose of DON makes evaluation of its therapeutic index difficult. DON given for five days at a dose of 5 mg per day to Patient F. J. had no untoward side effects. The same dose continued for nine days in the second patient, N. M., again produced no untoward side effects, but when the dose was increased to 10 mg per day, an asymptomatic duodenal ulcer developed after five days. Although DON administered in higher doses as chemotherapy for cancer results in a significant incidence of leukopenia, thrombocytopenia, nausea and vomiting (9) , no such toxic effects were observed during this study. The relatively high incidence of oral toxicity and peptic ulceration, even at relatively low doses, makes the use of DON imprudent in* managing patients who overproduce uric acid. This approach, however, of reducing excessive uric acid production by means of inhibitors of purine biosynthesis appears to be possible, and warrants a further search for a more specific inhibitor with a more favorable therapeutic index. 
